Nachweis der BRAF-V600E-Mutation beim metastasierten kolorektalen Karzinom: Ein QuIP-Ringversuch

Korinna Jöhrens, Josephine Fischer, Markus Möbs, Klaus Junker, Jutta Kirfel, Sven Perner, Silke Laßmann, Martin Werner, Vanessa Borgmann, Hendrik Bläker, Michael Hummel*

*Korrespondierende/r Autor/-in für diese Arbeit

Abstract

Round robin testing is an important instrument for quality assurance. Increasingly, this also applies to the results of molecular diagnostics in pathology, which directly influence therapy decisions in precision oncology. In metastatic colorectal carcinoma (mCRC), the focus has been on detecting KRAS and NRAS mutations, whose absence allows therapy with EGFR blocking antibodies. Recently, BRAF has been added as another predictive marker, since mCRC patients with BRAF V600E mutation benefit significantly from treatment with encorafenib (a BRAF inhibitor) in combination with cetuximab (anti-EGFR antibody) after systemic therapy. Due to the approval of this treatment in 2020, it is a pre-requisite that BRAF V600E mutation detection in diagnostic pathologies is reliably performed. Therefore, this round robin test with BRAF V600E testing either by immunohistochemistry or molecular methods was performed. The round robin test results demonstrate that molecular BRAF V600E detection is currently clearly superior to immunohistochemical detection.

Titel in ÜbersetzungDetection of BRAF V600E mutation in metastatic colorectal carcinoma: A QuIP round robin test
OriginalspracheDeutsch
ZeitschriftPathologe
Jahrgang43
Ausgabenummer2
Seiten (von - bis)126-134
Seitenumfang9
ISSN0172-8113
DOIs
PublikationsstatusVeröffentlicht - 03.2022

Fingerprint

Untersuchen Sie die Forschungsthemen von „Nachweis der BRAF-V600E-Mutation beim metastasierten kolorektalen Karzinom: Ein QuIP-Ringversuch“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren